Notice of Webinar and FAQs for NIAID Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) and Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required), RFA-AI-18-046 and RFA-AI-18-047
Notice NOT-AI-19-008 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 18, 2018 Category: Research Source Type: funding
Fc-Dependent Mechanisms of Antibody-Mediated Killing (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-18-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 5, 2018 Category: Research Source Type: funding
NIAID, NIDA, and ORIP Interest in Administrative Supplements to Address the Research and Resources Needed to Develop Vaccines Targeting Opioids
Notice NOT-AI-18-055 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 2, 2018 Category: Research Source Type: funding
Notice of Webinar and FAQs for NIAID Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) and Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required), RFA-AI-18-046 and RFA-AI-18-047
Notice NOT-AI-18-060 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 1, 2018 Category: Research Source Type: funding
Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)
Funding Opportunity RFA-AI-18-046 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit applications for the Vaccine Treatment and Evaluation Units (VTEUs) to implement clinical site protocols (clinical research, clinical trials) for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases as part of NIAID Infectious Diseases Clinical Research Consortium (IDCRC). A companion FOA solicits applications for the Leadership Group for the ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 1, 2018 Category: Research Source Type: funding
Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required)
Funding Opportunity RFA-AI-18-047 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to form a Leadership Group for an Infectious Diseases Clinical Research Consortium, hereafter referred to as the Leadership Group (LG), to support the planning and implementation of clinical research that addresses the scientific priorities of NIAID in evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases. A companion FOA sol...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 1, 2018 Category: Research Source Type: funding
Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-923 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 17, 2018 Category: Research Source Type: funding
Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers (U54 Clinical Trial Required)
Funding Opportunity RFA-CA-18-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism. Each proposed U54 Partnership C...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 28, 2018 Category: Research Source Type: funding
Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 13, 2018 Category: Research Source Type: funding
Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)
Funding Opportunity RFA-CA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 13, 2018 Category: Research Source Type: funding
Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-873 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infectio...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 24, 2018 Category: Research Source Type: funding
Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-872 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 24, 2018 Category: Research Source Type: funding
Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-859 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA uses the R01 grant mechanism, while the companion FOA,...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 18, 2018 Category: Research Source Type: funding
Advancing Research Needed to Develop a Universal Influenza Vaccine (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-858 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA uses the R21 grant mechanism, while the companion FOA,...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 18, 2018 Category: Research Source Type: funding
NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018: Soliciting Proposals for Antimicrobial Products, Novel Vaccines and Technologies Against Category A, B, and C Agents, and Universal Influenza Vaccines
Notice NOT-AI-18-048 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 12, 2018 Category: Research Source Type: funding
